Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Flexible Stenting Solutions or FSS, a developer of next-generation flexible stents, has received CE Mark for its FlexStent femoropopliteal self expanding stent system. Stent sizes include a complete matrix of five, six, seven and 8mm diameters with 30 through 150mm lengths in a six French delivery system.
Subscribe to our email newsletter
The FlexStent femoropopliteal self expanding stent system is indicated for the treatment of peripheral vascular lesions involving the superficial femoral and popliteal arteries.
The fully connected flexible FlexStent has coupled technology with clinical needs by providing a stent with superior durability, flexibility, and radial stiffness, while providing uniform scaffolding, the company said.
In addition to the CE Mark, FSS plans to submit an investigational device exemption (IDE) application to the FDA. FDA IDE approval will allow FSS to commence a US clinical trial to collect clinical data for FDA pre-market approval.
Janet Burpee, CEO of FSS, said: “This is a significant milestone for FSS. We have been working diligently in preparation for CE Mark on this system. We believe our platform technology will provide needed clinical solutions in the interventional radiology, cardiology and gastroenterology device marketplace.”